LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients

Hepatology, 05/17/2012

The efficacy of LecT–Hepa, a glyco–marker developed using glycoproteomics, for estimating liver fibrosis was demonstrated in a multicenter study. LecT–Hepa given by a combination of the 2 glyco–parameters is a reliable method for determining the fibrosis stage, and is a potential substitute for liver biopsy.


  • Overall, 183 CHC patients were recruited from 5 liver centers.
  • The parameters Aspergillus oryzae lectin [AOL]/Dature stramonium lectin [DSA] and Maackia amurensis lectin [MAL]/DSA were measured using a bedside clinical chemistry analyzer in order to calculate LecT-Hepa levels.
  • The data were compared with those of 7 other noninvasive biochemical markers and tests (hyaluronic acid, tissue inhibitor of metalloproteases-1, platelet count, APRI, Forns index, Fib-4 index, and Zeng's score) for assessing liver fibrosis using the receiver-operating characteristic curve.
  • LecT-Hepa correlated well with the fibrosis stage as determined by liver biopsy.


  • The area under the curve (AUC), sensitivity and specificity of LecT-Hepa were 0.802, 59.6%, and 89.9%, respectively, for significant fibrosis; 0.882, 83.3%, and 80.0%, respectively, for severe fibrosis; and 0.929, 84.6%, and 88.5%, respectively, for cirrhosis.
  • AUC scores of LecT-Hepa at each fibrosis stage were greater than those of the 7 aforementioned noninvasive tests and markers.

Print Article Summary Cat 2 CME Report